// App-Quantinova.ai

2535 : Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.

Researchers

Presenter

  • Lillian L. Siu

Principal Investigators

  • Antoine Italiano

  • Wilson H. Miller

  • Steven Blotner

  • Jianguo Zhi

  • Steven Middleton

  • Gwen L. Nichols

  • Yung-Jue Bang

  • Linda R. Mileshkin

  • Hal W. Hirte

  • Monica Reckner

  • Brian Higgins

  • Lori Jukofsky

  • Lin Chi Chen

  • Jean-Yves Blay

  • Jourik A. Gietema

Medical Centers

  • Hoffmann-La Roche Inc., Translational Clinical Research Center, New York, NY

  • Hoffmann-La Roche Inc., Translational Clinical Research Center, Oncology Translational Medicine Group, New York, NY

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • Hoffmann-La Roche Inc., Translational Clinical Research Center, New York, NYInstitut Bergonie, Bordeaux, FranceHoffmann-La Roche, Translational Clinical Research Center, Oncology Translational Medicine, New York, NY

  • Segal Cancer Center, Jewish General Hospital, Department of Oncology, McGill University, Montreal, QC, Canada

  • Centre Leon Berard, Lyon, France

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Canada

  • Netherlands

  • Australia

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Mouse double minute 2 homolog

  • p53

  • Growth differentiation factor 15

Drug/Treatment

  • RG7388

Outcome

  • Unknown

Study Design

  • pharmacokinetics

  • randomized

Phase

  • I

Study Id's

  • NCT01462175

Sponsors

  • Roche

  • Hoffmann-La Roche

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved